2024 World Conference on Lung Cancer (WCLC) - Posters-P2.17A.01 Treatment Outcomes after Access to Broad Molecular Tests, Targeted Agents and Immunotherapy in NSCLC Patients from Brazil

P2.17A.01 Treatment Outcomes after Access to Broad Molecular Tests, Targeted Agents and Immunotherapy in NSCLC Patients from Brazil

Back to course

Pdf Summary

The study by Filipe Visani investigates the impact of expanded access to broad molecular tests, targeted therapies, and immunotherapy on the treatment outcomes of advanced non-small cell lung cancer (NSCLC) patients in Brazil. The research was conducted at Oncoclínicas and focuses on changes observed following the introduction of broad next-generation sequencing (NGS) panels and PD-L1 testing, first facilitated by patient support programs sponsored by the pharmaceutical industry in Brazil since 2017, with broader access implemented in 2020.<br /><br />The primary objective was to evaluate shifts in first-line treatment choices between two periods: pre-broad NGS (2017-2019) and post-broad NGS (2020-2022). The study also aimed to assess treatment outcomes and the prevalence of key genetic alterations. It used a retrospective cohort design, analyzing real-world data from electronic medical records for survival outcomes and molecular profiling provided by OC Precision Medicine.<br /><br />Key findings include a notable increase in the utilization of combination immunotherapy (IO) and chemotherapy (CT), as well as targeted therapies (TKIs), alongside a reduction in the use of chemotherapy alone during the recent period. In patients whose molecular profiles were evaluated using institutional broad NGS panels, prevalent genetic alterations included KRAS mutations (28.4%), EGFR mutations (23.6%), and ALK fusions (6.4%).<br /><br />Survival analyses demonstrated that molecular profiling and the subsequent selection of tailored treatments, such as IO and TKIs, were linked to improved survival outcomes. This emphasizes the importance of molecular diagnostics in optimizing personalized treatment plans for NSCLC patients.<br /><br />The study concludes that systematic access to comprehensive molecular testing and personalized therapies can significantly enhance treatment effectiveness and patient survival rates in real-world settings.

Asset Subtitle

Filipe Visani

Meta Tag

Speaker Filipe Visani

Topic Global Health, Health Services & Health Economics

Keywords

NSCLC

broad molecular tests

targeted therapies

immunotherapy

next-generation sequencing

PD-L1 testing

genetic alterations

KRAS mutations

EGFR mutations

ALK fusions